{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:32:48Z","timestamp":1792672368868,"version":"4.5.0"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The cause of systemic lupus erythematosus (SLE) is unknown. IFN-\u03b1 has been suggested as a causative agent of SLE; however, it was not proven, and to what extent and how IFN-\u03b1 contributes to the disease is unknown. We studied the contribution of IFN-\u03b1 to SLE by generating inducible IFN-\u03b1 transgenic mice and directly show that conditional upregulation of IFN-\u03b1 alone induces a typical manifestation of SLE in the mice not prone to autoimmunity, such as serum immune complex, autoantibody against dsDNA (anti-dsDNA Ab), and the organ manifestations classical to SLE, such as immune complex\u2013deposited glomerulonephritis, classical splenic onion-skin lesion, alopecia, epidermal liquefaction, and positive lupus band test of the skin. In the spleen of mice, activated effector CD4 T cells, IFN-\u03b3\u2013producing CD8 T cells, B220+CD86+ cells, and CD11c+CD86+ cells were increased, and the T cells produced increased amounts of IL-4, IL-6, IL-17, and IFN-\u03b3 and decreased IL-2. In particular, activated CD3+CD4\u2212CD8\u2212 double-negative T cells positive for TCR\u03b1\u03b2, B220, CD1d-teteramer, PD-1, and Helios (that produced increased amounts of IFN-\u03b3, IL-4, IL-17, and TNF-\u03b1) were significantly expanded. They infiltrated into kidney and induced de novo glomerulonephritis and alopecia when transferred into naive recipients. Thus, sole upregulation of IFN-\u03b1 is sufficient to induce SLE, and the double-negative T cells expanded by IFN-\u03b1 are directly responsible for the organ manifestations, such as lupus skin disease or nephritis.<\/jats:p>","DOI":"10.4049\/jimmunol.1801617","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T20:45:11Z","timestamp":1563569111000},"page":"835-843","source":"Crossref","is-referenced-by-count":19,"title":["Conditional Upregulation of IFN-\u03b1 Alone Is Sufficient to Induce Systemic Lupus Erythematosus"],"prefix":"10.1093","volume":"203","author":[{"given":"Chieri","family":"Akiyama","sequence":"first","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Science , Kobe 654-0142 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsumiyama","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Science , Kobe 654-0142 ,","place":["Japan"]},{"name":"Institute for Rheumatic Diseases , Ashiya 659-0004 ,","place":["Japan"]},{"name":"Kyushu University Beppu Hospital , Beppu 874-0838 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Uchimura","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Science , Kobe 654-0142 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Science , Kobe 654-0142 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Science , Kobe 654-0142 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Institute for Rheumatic Diseases , Ashiya 659-0004 ,","place":["Japan"]},{"name":"Kyushu University Beppu Hospital , Beppu 874-0838 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Science , Kobe 654-0142 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hashiramoto","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Science , Kobe 654-0142 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean W","family":"Felsher","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine and Pathology, School of Medicine, Stanford University , Stanford, CA 94305"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"Department of Biophysics, Kobe University Graduate School of Health Science , Kobe 654-0142 ,","place":["Japan"]},{"name":"Institute for Rheumatic Diseases , Ashiya 659-0004 ,","place":["Japan"]},{"name":"Kyushu University Beppu Hospital , Beppu 874-0838 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"2025030417541066300_r1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"2025030417541066300_r2","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s10875-018-0543-6","article-title":"A brief historical perspective on the pathological consequences of excessive type I interferon exposure in vivo","volume":"38","author":"Crow","year":"2018","journal-title":"J. Clin. Immunol."},{"key":"2025030417541066300_r3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.autrev.2017.11.009","article-title":"Targeting interferons and their pathways in systemic lupus erythematosus","volume":"17","author":"Chasset","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"2025030417541066300_r4","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1073\/pnas.63.4.1102","article-title":"The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid","volume":"63","author":"Steinberg","year":"1969","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417541066300_r5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"2025030417541066300_r6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1126\/science.6176024","article-title":"Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon","volume":"216","author":"Preble","year":"1982","journal-title":"Science"},{"key":"2025030417541066300_r7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/art.1780250407","article-title":"Serum interferon levels in patients with systemic lupus erythematosus","volume":"25","author":"Ytterberg","year":"1982","journal-title":"Arthritis Rheum."},{"key":"2025030417541066300_r8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/art.1780350410","article-title":"Interferon-alpha in lupus psychosis","volume":"35","author":"Shiozawa","year":"1992","journal-title":"Arthritis Rheum."},{"key":"2025030417541066300_r9","first-page":"77","article-title":"A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients","volume":"66","author":"Shiozawa","year":"1986","journal-title":"Clin. Exp. Immunol."},{"key":"2025030417541066300_r10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0002-9343(83)91075-6","article-title":"Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction","volume":"74","author":"Winfield","year":"1983","journal-title":"Am. J. Med."},{"key":"2025030417541066300_r11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.287.6400.1165","article-title":"Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications","volume":"287","author":"Lebon","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"2025030417541066300_r12","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2025030417541066300_r13","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1371\/journal.pmed.0030491","article-title":"Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus","volume":"3","author":"Bauer","year":"2006","journal-title":"PLoS Med."},{"key":"2025030417541066300_r14","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417541066300_r15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J. Exp. Med."},{"key":"2025030417541066300_r16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/ard.2007.074765","article-title":"Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus","volume":"67","author":"Nikpour","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"2025030417541066300_r17","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1002\/art.24803","article-title":"Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study","volume":"60","author":"Bauer","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2025030417541066300_r18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2796.1990.tb00144.x","article-title":"Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour","volume":"227","author":"R\u00f6nnblom","year":"1990","journal-title":"J. Intern. Med."},{"key":"2025030417541066300_r19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","article-title":"Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors","volume":"115","author":"R\u00f6nnblom","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"2025030417541066300_r20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J. Hepatol."},{"key":"2025030417541066300_r21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-3476(05)80913-8","article-title":"Systemic lupus erythematosus in a child receiving long-term interferon therapy","volume":"120","author":"Tolaymat","year":"1992","journal-title":"J. Pediatr."},{"key":"2025030417541066300_r22","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/1097-0142(19911001)68:7<1536::AID-CNCR2820680713>3.0.CO;2-B","article-title":"Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia","volume":"68","author":"Schilling","year":"1991","journal-title":"Cancer"},{"key":"2025030417541066300_r23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/rheumatology\/33.8.787","article-title":"Systemic lupus erythematosus following interferon therapy","volume":"33","author":"Flores","year":"1994","journal-title":"Br. J. Rheumatol."},{"key":"2025030417541066300_r24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0090-1229(92)90250-R","article-title":"Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders","volume":"65","author":"Wandl","year":"1992","journal-title":"Clin. Immunol. Immunopathol."},{"key":"2025030417541066300_r25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/art.1780360224","article-title":"Appearance of anti-DNA antibodies in patients treated with interferon-alpha","volume":"36","author":"Ehrenstein","year":"1993","journal-title":"Arthritis Rheum."},{"key":"2025030417541066300_r26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/ng.748","article-title":"Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature","volume":"43","author":"Briggs","year":"2011","journal-title":"Nat. Genet."},{"key":"2025030417541066300_r27","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.39110","article-title":"Brief report: IFIH1 mutation causes systemic lupus erythematosus with selective IgA deficiency","volume":"67","author":"Van Eyck","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"2025030417541066300_r28","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.4049\/jimmunol.174.5.2499","article-title":"IFN-\u03b1 induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB\/c mice","volume":"174","author":"Mathian","year":"2005","journal-title":"J. Immunol."},{"key":"2025030417541066300_r29","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1002\/eji.200837925","article-title":"Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice","volume":"38","author":"Fairhurst","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"2025030417541066300_r30","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/art.24414","article-title":"Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation","volume":"60","author":"Ramanujam","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2025030417541066300_r31","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.4049\/jimmunol.1000466","article-title":"B Cell and BAFF dependence of IFN-\u03b1-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice","volume":"186","author":"Jacob","year":"2011","journal-title":"J. Immunol."},{"key":"2025030417541066300_r32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0896-8411(02)00109-9","article-title":"Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice","volume":"20","author":"Braun","year":"2003","journal-title":"J. Autoimmun."},{"key":"2025030417541066300_r33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.20021996","article-title":"Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice","volume":"197","author":"Santiago-Raber","year":"2003","journal-title":"J. Exp. Med."},{"key":"2025030417541066300_r34","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.23023","article-title":"Deficiency of the type I interferon receptor protects mice from experimental lupus","volume":"56","author":"Nacionales","year":"2007","journal-title":"Arthritis Rheum."},{"key":"2025030417541066300_r35","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.4049\/jimmunol.1201477","article-title":"Anti-IFN-\u03b1\/\u03b2 receptor antibody treatment ameliorates disease in lupus-predisposed mice","volume":"189","author":"Baccala","year":"2012","journal-title":"J. Immunol."},{"key":"2025030417541066300_r36","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.173.3.2134","article-title":"Type I IFN protects against murine lupus","volume":"173","author":"Hron","year":"2004","journal-title":"J. Immunol."},{"key":"2025030417541066300_r37","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.21307","article-title":"Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes","volume":"52","author":"Li","year":"2005","journal-title":"Arthritis Rheum."},{"key":"2025030417541066300_r38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"2025030417541066300_r39","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"2025030417541066300_r40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"2025030417541066300_r41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1097-2765(00)80367-6","article-title":"Reversible tumorigenesis by MYC in hematopoietic lineages","volume":"4","author":"Felsher","year":"1999","journal-title":"Mol. Cell"},{"key":"2025030417541066300_r42","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4049\/jimmunol.125.2.763","article-title":"Detection and partial characterization of circulating immune complexes with solid-phase anti-C3","volume":"125","author":"Pereira","year":"1980","journal-title":"J. Immunol."},{"key":"2025030417541066300_r43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nbt1412","article-title":"Treatment of arthritis with a selective inhibitor of c-Fos\/activator protein-1","volume":"26","author":"Aikawa","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"2025030417541066300_r44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited. [Published erratum appears in 2004 J. Am. Soc. Nephrol. 15: 835\u2013836.]","volume":"15","author":"Weening","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"2025030417541066300_r45","doi-asserted-by":"crossref","first-page":"e8382","DOI":"10.1371\/journal.pone.0008382","article-title":"Self-organized criticality theory of autoimmunity","volume":"4","author":"Tsumiyama","year":"2009","journal-title":"PLoS One"},{"key":"2025030417541066300_r46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/bioinformatics\/19.2.185","article-title":"A comparison of normalization methods for high density oligonucleotide array data based on variance and bias","volume":"19","author":"Bolstad","year":"2003","journal-title":"Bioinformatics"},{"key":"2025030417541066300_r47","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol."},{"key":"2025030417541066300_r48","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/ng1032","article-title":"Microarray data normalization and transformation","volume":"32","author":"Quackenbush","year":"2002","journal-title":"Nat. Genet."},{"key":"2025030417541066300_r49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2144\/03342mt01","article-title":"TM4: a free, open-source system for microarray data management and analysis","volume":"34","author":"Saeed","year":"2003","journal-title":"Biotechniques"},{"key":"2025030417541066300_r50","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. [Published erratum appears in 2016 Cell 165: 1548\u20131550.]","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"2025030417541066300_r51","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0008-8749(90)90047-U","article-title":"CD4-CD8- human T cells: phenotypic heterogeneity and activation requirements of freshly isolated \u201cdouble-negative\u201d T cells","volume":"128","author":"Bender","year":"1990","journal-title":"Cell. Immunol."},{"key":"2025030417541066300_r52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coi.2006.07.001","article-title":"CD1d- and MR1-restricted invariant T cells: of mice and men","volume":"18","author":"Treiner","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"2025030417541066300_r53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1191\/0961203302lu235oa","article-title":"Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: activation markers","volume":"11","author":"Anand","year":"2002","journal-title":"Lupus"},{"key":"2025030417541066300_r54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4049\/jimmunol.143.1.103","article-title":"T cell receptor alpha\/beta expressing double-negative (CD4-\/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis","volume":"143","author":"Shivakumar","year":"1989","journal-title":"J. Immunol."},{"key":"2025030417541066300_r55","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.4049\/jimmunol.159.9.4628","article-title":"Fas ligand expression and function in systemic lupus erythematosus","volume":"159","author":"McNally","year":"1997","journal-title":"J. Immunol."},{"key":"2025030417541066300_r56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.immuni.2014.01.005","article-title":"Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection","volume":"40","author":"Crawford","year":"2014","journal-title":"Immunity"},{"key":"2025030417541066300_r57","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.4049\/jimmunol.129.6.2612","article-title":"Abnormalities induced by the mutant gene Ipr: expansion of a unique lymphocyte subset","volume":"129","author":"Morse","year":"1982","journal-title":"J. Immunol."},{"key":"2025030417541066300_r58","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0065-2776(08)60342-9","article-title":"Murine models of systemic lupus erythematosus","volume":"37","author":"Theofilopoulos","year":"1985","journal-title":"Adv. Immunol."},{"key":"2025030417541066300_r59","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.139.7.2200","article-title":"T cell lineages in the thymus of lpr\/lpr mice. Evidence for parallel pathways of normal and abnormal T cell development","volume":"139","author":"Budd","year":"1987","journal-title":"J. Immunol."},{"key":"2025030417541066300_r60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1084\/jem.172.1.7","article-title":"Liver is a possible site for the proliferation of abnormal CD3+4-8- double-negative lymphocytes in autoimmune MRL-lpr\/lpr mice","volume":"172","author":"Ohteki","year":"1990","journal-title":"J. Exp. Med."},{"key":"2025030417541066300_r61","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.4049\/jimmunol.0901533","article-title":"Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype","volume":"183","author":"Crisp\u00edn","year":"2009","journal-title":"J. Immunol."},{"key":"2025030417541066300_r62","doi-asserted-by":"crossref","first-page":"31880","DOI":"10.1074\/jbc.M113.508655","article-title":"cAMP-responsive element modulator \u03b1 (CREM\u03b1) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease","volume":"288","author":"Hedrich","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2025030417541066300_r63","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1074\/jbc.M113.523605","article-title":"cAMP responsive element modulator (CREM) \u03b1 mediates chromatin remodeling of CD8 during the generation of CD3+ CD4- CD8- T cells","volume":"289","author":"Hedrich","year":"2014","journal-title":"J. Biol. Chem."},{"key":"2025030417541066300_r64","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.4049\/jimmunol.161.4.1686","article-title":"TCR ligation on CD8+ T cells creates double-negative cells in vivo","volume":"161","author":"Mehal","year":"1998","journal-title":"J. Immunol."},{"key":"2025030417541066300_r65","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.284.5417.1187","article-title":"Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death","volume":"284","author":"Pestano","year":"1999","journal-title":"Science"},{"key":"2025030417541066300_r66","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.4049\/jimmunol.1402775","article-title":"Programmed cell death 1 and Helios distinguish TCR-\u03b1\u03b2+ double-negative (CD4-CD8-) T cells that derive from self-reactive CD8 T cells","volume":"194","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2015","journal-title":"J. Immunol."},{"key":"2025030417541066300_r67","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/eji.201546056","article-title":"Pro-inflammatory self-reactive T cells are found within murine TCR-\u03b1\u03b2(+) CD4(-) CD8(-) PD-1(+) cells","volume":"46","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"2025030417541066300_r68","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.4049\/jimmunol.162.10.5747","article-title":"A model for the origin of TCR-alphabeta+ CD4-CD8- B220+ cells based on high affinity TCR signals","volume":"162","author":"Mixter","year":"1999","journal-title":"J. Immunol."},{"key":"2025030417541066300_r69","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.4049\/jimmunol.1700332","article-title":"Induction of systemic autoimmunity by a xenobiotic requires endosomal TLR trafficking and signaling from the late endosome and endolysosome but not type I IFN","volume":"199","author":"Pollard","year":"2017","journal-title":"J. Immunol."},{"key":"2025030417541066300_r70","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.celrep.2018.09.001","article-title":"IFN\u03b1 impairs autophagic degradation of mtDNA promoting autoreactivity of SLE monocytes in a STING-dependent fashion","volume":"25","author":"Gkirtzimanaki","year":"2018","journal-title":"Cell Rep."},{"key":"2025030417541066300_r71","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","article-title":"Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6","volume":"19","author":"Jego","year":"2003","journal-title":"Immunity"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/203\/4\/835\/61887496\/ji1801617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/203\/4\/835\/61887496\/ji1801617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:16:26Z","timestamp":1741115786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/203\/4\/835\/7952471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1801617","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,8]]}}}